Selecting IVF embryos for normal numbers of chromosomes can significantly increase pregnancy rates

BlueGnome is pleased to announce the results of the first randomised prospective IVF study of pre-implantation chromosome analysis using their 24sure array platform. The study by Yang et al (Pacific Reproductive Center,Torrance, USA) has demonstrated that selectively implanting euploid embryos, with a normal number of chromosomes, significantly increases pregnancy rates.
The study blindly randomised 103 IVF cycles. In the treatment group of 55 cycles, 24sure analysis of day 5 biopsies was used to selectively implant a single euploid embryo (as recommended by IVF regulatory bodies such as the HEFA), while in the control group of 48 cycles single embryos were selected using existing morphological scorecard approaches. The ongoing pregnancy rate, after 20 weeks, per cycle started was 69.1% in the 24sure treatment group vs 41.7% in the control group. This extremely promising result provides direct evidence that 24sure analysis can deliver a 65% increase in pregnancy rates, even in younger patients with more favourable IVF outcomes. Further randomised studies are needed and are underway.
‘This study provides crucial evidence that 24 chromosome aneuploidy screening, using 24sure, can offer a dramatic benefit to IVF success rates. While further studies are still needed, this result is incredibly exciting because it indicates for the first time that 24 chromosome screening and single embryo transfer has the potential to become the default standard of care for all IVF cycles worldwide.’ Nick Haan, CEO, BlueGnome Ltd, BlueGnome